The Patent Finder
JP

JMD Pharma Creativity, LLC

First filing 2022
OverviewNotableFeesChangesPatent listSources & methods

0 patents currently held, every record listed here

7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

This portfolio holds none of the 7 US patents in force on its record. from the record

Of the 7 now held by other companies, 5 name Atai Therapeutics Inc. as their current owner, and 2 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end

When these terms end

Each bar runs from grant to computed term end. 2023 to 2042.
US 11,926,574 Dimethoxyphenylalkylamine Activators of Serotonin Receptors Jun 8, 2042
US 11,643,391 Novel Prodrugs and Conjugates of Dimethyltryptamine Jun 9, 2042
US 12,065,405 Prodrugs and Conjugates of Dimethyltryptamine Jun 9, 2042
US 11,845,736 Prodrugs of Mdma, Mda, and Derivatives Thereof Oct 3, 2042
US 11,827,580 Aminotetraline Activators of Serotonin Receptors Dec 27, 2042
US 11,912,680 Nitric Oxide Releasing Prodrugs of Mda and Mdma Dec 28, 2042
US 12,012,381 Dimethyltryptamine Analogues as Nitric Oxide Delivery Drugs Dec 28, 2042
20272031203520392042
3 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2042.
Ends Jun 2042 · Medium confidence
Also notable
The most cited patent in this portfolio, cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2042.
Ends Dec 2042 · High confidence
Also notable
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2042.
now held by Empathbio, Inc.
Ends Oct 2042 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Also on record: 7 patents in force now held by others · 3 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited